ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,165Medicare Part D Prescriptions Filled, Including Refills

Rank: 178 out of 1006

$766K Total Retail Price of All Prescriptions

Rank: 88 out of 1006

544 Patients Receiving at Least One Drug in Part D
74%Patients 65 Years and Older
54% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 544 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

9% of this provider’s 544 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

0% of this provider’s 5,045 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

30% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$94 was the average price of a prescription from this provider, compared to $71 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
LEVOTHYROXINE SODIUM 358 183 1 2
LISINOPRIL 227 161 2 3
WARFARIN SODIUM 214 212 3 8
METFORMIN HCL 203 144 4 10
ATORVASTATIN CALCIUM 186 159 5 5
METOPROLOL TARTRATE 171 124 6 7
POLYETHYLENE GLYCOL 3350 150 0 7 91
OMEPRAZOLE 144 91 8 9
SIMVASTATIN 140 94 9 1
FUROSEMIDE 123 82 10 6
DIVALPROEX SODIUM 109 0 11 53
LISINOPRIL-HYDROCHLOROTHIAZIDE 104 87 12 38
GABAPENTIN 104 70 12 20
TAMSULOSIN HCL 102 83 14 23
METOPROLOL SUCCINATE 95 88 15 12
SUBOXONE 89 0 16 218
RANITIDINE HCL 88 46 17 63
HYDROCHLOROTHIAZIDE 88 78 17 11
CRESTOR 86 51 19 18
PREDNISONE 85 70 20 33
ZETIA 85 74 20 51
AMLODIPINE BESYLATE 84 80 22 4
POTASSIUM CHLORIDE 80 49 23 30
ZOLPIDEM TARTRATE 80 70 23 14
LAMOTRIGINE 78 0 25 119
DOXYCYCLINE HYCLATE 71 43 26 130
ADVAIR DISKUS 71 56 26 37
NEXIUM 70 63 28 28
CARBAMAZEPINE 65 18 29 124
PANTOPRAZOLE SODIUM 64 47 30 32
ALLOPURINOL 63 59 31 31
LITHIUM CARBONATE 61 0 32 187
HYDROCODONE-ACETAMINOPHEN 61 56 S3 32 25
DIGOXIN 61 61 32 52
ALENDRONATE SODIUM 60 0 35 29
SINGULAIR 60 35 35 82
AZITHROMYCIN 57 48 37 39
LOSARTAN POTASSIUM 56 51 38 22
CYMBALTA 55 35 39 41
NAMENDA 55 55 39 34
CHLORHEXIDINE GLUCONATE 54 0 41 136
GLIPIZIDE ER 53 52 42 108
ATENOLOL 53 53 42 13
GLIPIZIDE 52 41 44 69
PROAIR HFA 52 33 44 64
PRAVASTATIN SODIUM 51 37 46 15
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 16, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.